AR043248A1 - Sistema terapeutico transdermico estable a los rayos uv - Google Patents

Sistema terapeutico transdermico estable a los rayos uv

Info

Publication number
AR043248A1
AR043248A1 ARP040100539A ARP040100539A AR043248A1 AR 043248 A1 AR043248 A1 AR 043248A1 AR P040100539 A ARP040100539 A AR P040100539A AR P040100539 A ARP040100539 A AR P040100539A AR 043248 A1 AR043248 A1 AR 043248A1
Authority
AR
Argentina
Prior art keywords
therapeutic system
transdermal therapeutic
layer
stable transdermal
gestoden
Prior art date
Application number
ARP040100539A
Other languages
English (en)
Inventor
Jochen Schumacher
Susse Manfred Dr
Dr Dittgen Michael Prof
Mletzko Stephan Dr
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP03003888A external-priority patent/EP1449526A1/de
Priority claimed from EP03004061A external-priority patent/EP1452173A1/de
Application filed by Schering Ag filed Critical Schering Ag
Publication of AR043248A1 publication Critical patent/AR043248A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Abstract

Sistema terapéutico transdérmico que presenta la siguiente sucesión de capas desde el lado alejado de la piel; capa base, capa adhesiva que contiene agente absorbente de rayos UV, capa separadora y finalmente una matriz de una o dos capas que contiene sustancias activas (preferentemente Gestoden o Levonorgestrel), cuya superficie adhesiva está cubierta con una película protectora despegable.
ARP040100539A 2003-02-21 2004-02-20 Sistema terapeutico transdermico estable a los rayos uv AR043248A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03003888A EP1449526A1 (de) 2003-02-21 2003-02-21 UV-stabiles transdermales Pflaster
EP03004061A EP1452173A1 (de) 2003-02-25 2003-02-25 UV-stabiles transdermales Pflaster

Publications (1)

Publication Number Publication Date
AR043248A1 true AR043248A1 (es) 2005-07-20

Family

ID=32910125

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100539A AR043248A1 (es) 2003-02-21 2004-02-20 Sistema terapeutico transdermico estable a los rayos uv

Country Status (31)

Country Link
US (3) US8486443B2 (es)
EP (1) EP1594483B1 (es)
JP (1) JP4528296B2 (es)
KR (1) KR100704825B1 (es)
AR (1) AR043248A1 (es)
AT (1) ATE333271T1 (es)
AU (1) AU2004212675B2 (es)
BR (1) BRPI0407615B8 (es)
CA (1) CA2515918C (es)
CR (1) CR7952A (es)
CY (1) CY1105716T1 (es)
DE (1) DE502004000988D1 (es)
DK (1) DK1594483T3 (es)
EA (1) EA008098B1 (es)
EC (1) ECSP056030A (es)
ES (1) ES2270345T3 (es)
HK (1) HK1085394A1 (es)
HR (1) HRP20050828B1 (es)
IL (1) IL170295A (es)
IS (1) IS2541B (es)
ME (2) ME00147B (es)
MX (1) MXPA05008778A (es)
NO (1) NO336108B1 (es)
NZ (1) NZ541807A (es)
PE (1) PE20041028A1 (es)
PL (1) PL219030B1 (es)
PT (1) PT1594483E (es)
RS (1) RS50428B (es)
SI (1) SI1594483T1 (es)
UY (1) UY28189A1 (es)
WO (1) WO2004073696A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00147B (me) 2003-02-21 2010-10-10 Schering Ag Uv-stabilni transdermalni flasteri
US8668925B2 (en) * 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
EP1796651B1 (en) * 2004-08-20 2015-05-20 3M Innovative Properties Company Transdermal drug delivery device with translucent protective film
US8962013B2 (en) * 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
EP1719504A1 (de) * 2005-05-02 2006-11-08 Schering AG Festes transdermales therapeutisches System mit UV-Absorber
WO2010009122A1 (en) * 2008-07-14 2010-01-21 Surmodics, Inc. Medical devices and methods for delivery of nucleic acids
DE102010040299A1 (de) * 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
ES2617334T3 (es) * 2010-09-06 2017-06-16 Bayer Intellectual Property Gmbh Parches transdérmicos de dosificación baja con liberación elevada de fármaco
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
SG11201805570WA (en) 2015-12-30 2018-07-30 Corium Int Inc Systems and methods for long term transdermal administration
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
DE102020104907A1 (de) * 2020-02-25 2021-08-26 Berliner Glas GmbH Verfahren zur Herstellung eines Bauelements durch atomares Diffusionsbonden

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5939827A (ja) 1982-08-27 1984-03-05 Nitto Electric Ind Co Ltd 医療用外用部材
JPS6069014A (ja) 1983-09-27 1985-04-19 Nitto Electric Ind Co Ltd 皮膚疾患治療用貼付剤
US4573996A (en) * 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
JPS60166611A (ja) 1984-02-10 1985-08-29 Nitto Electric Ind Co Ltd 疾患治療用部材
US5560922A (en) * 1986-05-30 1996-10-01 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process
US5023084A (en) 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
CH674618A5 (es) 1987-04-02 1990-06-29 Ciba Geigy Ag
US5538736A (en) * 1987-04-28 1996-07-23 Lts Lohmann Therapie-Systeme Gmbh Active substance-containing plaster for the controlled administration of active substances to the skin
US5128284A (en) * 1987-10-23 1992-07-07 Allied-Signal Inc. Preparation of lanthanum chromite powders by sol-gel
DE58909570D1 (de) * 1988-10-27 1996-02-22 Schering Ag Mittel zur transdermalen applikation enthaltend gestoden
EP0453396B1 (de) 1990-03-30 1995-12-13 Ciba SC Holding AG Lackzusammensetzungen
EP0483370B1 (en) 1990-05-17 1995-03-29 Hisamitsu Pharmaceutical Co., Inc. Percutaneous preparation containing estradiol
GB9021674D0 (en) * 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
US5512292A (en) * 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
EP0555360A1 (en) * 1990-10-29 1993-08-18 Alza Corporation Transdermal contraceptive formulations, methods and devices
JP3112707B2 (ja) 1991-07-25 2000-11-27 日本電気株式会社 監視システム用ポーリング方式
DE4336557C2 (de) * 1993-05-06 1997-07-17 Lohmann Therapie Syst Lts Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
DE4329242A1 (de) * 1993-08-26 1995-03-02 Schering Ag Mittel zur transdermalen Applikation enthaltend Gestodenester
DE4336299A1 (de) * 1993-10-25 1995-05-11 Arbo Robotron Medizin Technolo Gelkörper zur percutanen Verabreichung, insbesondere von Medikamenten
DE4403487C2 (de) * 1994-02-04 2003-10-16 Lohmann Therapie Syst Lts Arznei-Pflaster mit UV-vernetzbaren Acrylat-Copolymeren
DE4405898A1 (de) * 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
WO1996015776A1 (fr) 1994-11-18 1996-05-30 Hisamitsu Pharmaceutical Co., Inc. Timbre absorbable par voie percutanee
JP3908795B2 (ja) * 1994-11-29 2007-04-25 久光製薬株式会社 ケトチフェン含有経皮投与製剤
JP3534775B2 (ja) * 1995-06-07 2004-06-07 オーソ―マクニール ファーマシューティカル，インコーポレイテッド １７−デアセチルノルゲスチマートを単独でまたはエストロゲンと組み合わせて投与するための経皮パッチおよび方法
US5906830A (en) * 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
JP3626275B2 (ja) 1996-04-09 2005-03-02 Ｊｓｒ株式会社 光硬化性樹脂組成物
US5762956A (en) * 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
JP4346696B2 (ja) 1996-05-28 2009-10-21 久光製薬株式会社 経皮治療用装置
JP3434135B2 (ja) 1996-07-11 2003-08-04 アルパイン株式会社 ナビゲーション装置
DE19701949A1 (de) * 1997-01-13 1998-07-16 Jenapharm Gmbh Transdermales therapeutisches System
JPH10265371A (ja) * 1997-03-25 1998-10-06 Sekisui Chem Co Ltd 経皮吸収貼付剤
EP0976405A4 (en) 1997-04-16 2000-12-06 Hisamitsu Pharmaceutical Co BASIC COMPOSITION FOR PERCUTANE ABSORPTION AND PERCUTANE ABSORBABLE PREPARATION THAT CONTAINS BASIC COMPOSITION
US5948433A (en) * 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
DE19827732A1 (de) 1998-06-22 1999-12-23 Rottapharm Bv Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie
JP4399044B2 (ja) 1998-10-14 2010-01-13 久光製薬株式会社 吸収促進剤及び該吸収促進剤を有してなる経皮吸収製剤
WO2000045797A1 (en) 1999-02-02 2000-08-10 Ortho-Mcneil Pharmaceutical, Inc. Method of manufacture for transdermal matrices
DE19906152B4 (de) 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
DE19912623A1 (de) 1999-03-20 2000-09-28 Lohmann Therapie Syst Lts Verfahren zur Erhöhung der Stabilität bei Lagerung und/oder Anwendung lichtempfindlicher therapeutischer Systeme oder deren Bestandteile
US8173592B1 (en) 1999-03-31 2012-05-08 Zentaris Ivf Gmbh Method for a programmed controlled ovarian stimulation protocol
WO2001001990A1 (fr) 1999-07-01 2001-01-11 Hisamitsu Pharmaceutical Co., Inc. Preparation adhesive pour absorption percutanee
JP4841781B2 (ja) 1999-11-24 2011-12-21 アジル・セラピューティクス・インコーポレイテッド 改良された経皮的避妊薬送達系および方法
AU3104301A (en) * 2000-01-20 2001-07-31 Noven Pharmaceuticals, Inc. Compositions and methods to effect the release profile in the transdermal administration of active agents
BRPI0109198B8 (pt) 2000-03-17 2021-05-25 Hisamitsu Pharmaceutical Co emplastro tendo um apoio
WO2001095889A1 (fr) * 2000-06-13 2001-12-20 Hisamitsu Pharmaceutical Co., Inc. Platre
DE10053375C1 (de) * 2000-10-27 2002-01-24 Lohmann Therapie Syst Lts Transdermale therapeutische Systeme mit lichtempfindlichen Wirkstoffen
US20020106402A1 (en) 2000-12-05 2002-08-08 Hartwig Rod Lawson Crystallization inhibition of drugs in transdermal drug delivery systems and methods of use
JP2005519962A (ja) 2002-03-11 2005-07-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ スルファターゼを阻害する継続的プロゲストゲン避妊レジメン
US6872401B2 (en) 2002-03-28 2005-03-29 L'oreal Cosmetic/dermatological compositions comprising a tetrahydrocurcuminoid and an amide oil
US7470452B1 (en) * 2002-06-13 2008-12-30 E. I. Du Pont De Nemours & Company Process for multilayer coating of substrates
US7032980B2 (en) * 2002-06-27 2006-04-25 The Little Tikes Company Non-slip wheel for a child's toy
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
ME00147B (me) 2003-02-21 2010-10-10 Schering Ag Uv-stabilni transdermalni flasteri
EP1452173A1 (de) 2003-02-25 2004-09-01 Schering AG UV-stabiles transdermales Pflaster
US8524272B2 (en) * 2003-08-15 2013-09-03 Mylan Technologies, Inc. Transdermal patch incorporating active agent migration barrier layer
EP1660294B1 (en) * 2003-08-25 2008-12-03 BFS Diversified Products, LLC Method and apparatus to monitor the compressive strength of insulation boards
ATE421541T1 (de) * 2003-09-11 2009-02-15 Ciba Holding Inc Auf wasser basierende konzentrierte produktformen von lichtschutzmitteln, hergestellt nach einer heterophasen-polymerisationstechnik
US20050129756A1 (en) 2003-12-10 2005-06-16 Hans-Peter Podhaisky UV-stable, liquid or semisolid transdermal pharmaceutical preparation with light sensitive active ingredient
UA89766C2 (en) 2003-12-12 2010-03-10 Байер Шеринг Фарма Акциенгезельшафт Transdermal delivery system of gestodene
US8668925B2 (en) * 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
JP4965263B2 (ja) 2003-12-12 2012-07-04 バイエル ファーマ アクチエンゲゼルシャフト 浸透増強剤を必要としないホルモンの経皮送達
JP4504109B2 (ja) 2004-06-15 2010-07-14 株式会社新陽社 画像表示装置及び画素構成体
US8962013B2 (en) * 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
EP1719504A1 (de) 2005-05-02 2006-11-08 Schering AG Festes transdermales therapeutisches System mit UV-Absorber
EP2349230A2 (en) 2008-10-06 2011-08-03 Mylan Technologies, Inc. Amorphous rotigotine transdermal system

Also Published As

Publication number Publication date
NO336108B1 (no) 2015-05-18
EA200501224A1 (ru) 2006-04-28
CA2515918A1 (en) 2004-09-02
HRP20050828A2 (en) 2006-03-31
AU2004212675A1 (en) 2004-09-02
EP1594483B1 (de) 2006-07-19
EA008098B1 (ru) 2007-02-27
UY28189A1 (es) 2004-04-30
IL170295A (en) 2010-05-31
US20060251707A1 (en) 2006-11-09
HK1085394A1 (en) 2006-08-25
CY1105716T1 (el) 2010-12-22
US9095691B2 (en) 2015-08-04
US20150335658A1 (en) 2015-11-26
CR7952A (es) 2006-02-06
AU2004212675B2 (en) 2006-06-01
ME00147B (me) 2010-10-10
EP1594483A1 (de) 2005-11-16
BRPI0407615B1 (pt) 2018-02-14
PT1594483E (pt) 2006-12-29
SI1594483T1 (sl) 2006-12-31
NZ541807A (en) 2009-07-31
JP4528296B2 (ja) 2010-08-18
IS8031A (is) 2005-09-15
RS50428B (sr) 2009-12-31
BRPI0407615A (pt) 2006-02-14
MXPA05008778A (es) 2006-05-25
CA2515918C (en) 2010-11-16
DE502004000988D1 (de) 2006-08-31
PL219030B1 (pl) 2015-03-31
US20130226113A1 (en) 2013-08-29
HRP20050828B1 (hr) 2013-10-25
PE20041028A1 (es) 2005-02-18
NO20054321L (no) 2005-09-20
KR100704825B1 (ko) 2007-04-09
KR20050103499A (ko) 2005-10-31
WO2004073696A1 (de) 2004-09-02
ECSP056030A (es) 2006-01-27
ES2270345T3 (es) 2007-04-01
ATE333271T1 (de) 2006-08-15
JP2006518348A (ja) 2006-08-10
US8486443B2 (en) 2013-07-16
PL378035A1 (pl) 2006-02-20
RS20050639A (en) 2007-09-21
IS2541B (is) 2009-09-15
MEP14008A (en) 2010-06-10
DK1594483T3 (da) 2006-11-20
BRPI0407615B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
AR043248A1 (es) Sistema terapeutico transdermico estable a los rayos uv
ES2543977T3 (es) Sistema terapéutico transdérmico para la administración del principio activo buprenorfina
AR009516A1 (es) Un dispositivo de parche de matriz adhesiva sensible a la presion, un metodo para preparar dicho dispositivo y un metodo para emplear dichodispositivo en el suministro transdermico de una droga.
AR097045A2 (es) Sistema terapéutico transdérmico
AR018282A1 (es) Aposito de matriz adhesiva sensible a la presion para el tratamiento de infecciones de las unas
ES2147858T3 (es) Matriz para el suministro transdermico de farmacos.
CY1106411T1 (el) Διαδepμικο θepαπευτικο συστημα με fentanyl
JP2005502430A5 (es)
AR011577A1 (es) Composicion para la administracion transdermica de una droga esteroide y formulacion transdermica que la incluye
AR050621A1 (es) Sistema terapeutico transdermal con una capa adherente procedimiento para el siliconado de una capa de respaldo y empleo de la capa de respaldo
BR0307025A (pt) Ministrador laminado de inseticida, e, uso do mesmo
AR033748A1 (es) Un dispositivo para la administracion transdermica de sustancias farmacologicamente activas que comprende dos capas adhesivas superpuestas y un procedimiento para prepararlo
AR041098A1 (es) Construccion de un refuerzo multilaminado
AR070031A1 (es) Sistemas de administracion transdermicos de droga ketotifen y metodos para el tratamiento de enfermedades oftalmicas
AR054012A1 (es) Sistema terapeutico transdermico para la adminstracion de analgesicos
AR035688A1 (es) Sistema terapeutico transdermal, con un contenido de nicotina
ES2045377T3 (es) Preparacion percutanea de tulobuterol.
IT1312088B1 (it) Cerotto per uso topico contenente eparina e diclofenac.
BR0313092A (pt) Sistema de liberação transdérmica aperfeiçoado
ES2523663T3 (es) Sistema terapéutico transdérmico sólido con un agente absorbente de los rayos UV
AR039137A1 (es) Unidad coherente de sistemas terapeuticos transdermicos separables
AR028525A1 (es) Sistema terapeutico transdermal para la administracion de lerisetron
ES2063172T3 (es) Sistema terapeutico superficial con una sustancia activa antineoplasica, en especial 5-fluoruracilo.
PT1284718E (pt) Sistema terapeutico transdermal oclusivo com uma camada de reforco nao oclusiva
ES2523428T3 (es) Parche para administración transdérmica

Legal Events

Date Code Title Description
FC Refusal